A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505608-43-00

Acronym

I7P-MC-DSAF

Enrollment

Registered

2024-06-17

Start date

2024-07-04

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Hidradenitis Suppurativa

Brief summary

Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [Time Frame: Week 16]

Interventions

DRUGEltrekibart

DRUG0.9% sodium chloride

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [Time Frame: Week 16]	—

Countries

Germany, Greece, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026